Krystal Biotech to Present at Upcoming Cantor Fitzgerald and Ladenburg Thalmann Conferences

September 25, 2018

PITTSBURGH, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chief executive officer, will be presenting at the Cantor Fitzgerald Global Healthcare Conference 2018 and the Ladenburg Thalmann 2018 Healthcare Conference.  

Details for the conferences and presentations are as follows:

Cantor Fitzgerald Global Healthcare Conference 2018
    Monday, Oct. 1
8:20 – 8:50 a.m. ET
InterContinental New York Barclay Hotel
Ladenburg Thalmann 2018 Healthcare Conference
    Tuesday, Oct. 2
9:30 – 9:55 a.m. ET
Sofitel New York, Track 5 – Montmartre

About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the potential of KB103 to treat the underlying causes of DEB, the timetable for bringing GMP manufacturing in-house and the potential for rapid development of the company’s clinical programs.  You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Krystal’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Krystal’s filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and Form 10-K, as amended from time to time, under the caption “Risk Factors.” 


Ashley R. Robinson 
LifeSci Advisors 

Darren Opland, PhD
LifeSci Public Relations 

Source: Krystal Biotech, Inc.


Source: Krystal Biotech, Inc.